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um adherence and no patients (0%) scored high adherence. 
Younger patients (aged 30–50 years) had lower adherence 
than older patients (>50 years) [odds ratio (OR) 1.05; 95% 
confidence interval (CI) 1.01–1.09] for every extra year; p < 
0.01). Those without diabetes, i.e. 113 (56.5%), were less like-
ly to report medium adherence than those with diabetes (OR 
0.42; 95% CI 0.23–0.75; p < 0.01). Low statin adherence was 
associated with higher levels of plasma cholesterol (p < 
0.001) and low-density lipoprotein (p < 0.01).  Conclusion: In 
this study, there was a high prevalence of low statin adher-
ence, especially among younger patients with fewer con-
comitant diseases. The results indicated an inverse relation-
ship between statin adherence and CHD risk profile. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 Cardiovascular diseases are recognised as major con-
tributors to global mortality and morbidity. Coronary 
heart disease (CHD) has emerged as the leading cause of 
premature death worldwide, each year claiming approxi-
mately 3.8 and 3.4 million deaths of men and women, 
respectively  [1] . CHD continues to be a major health issue 
in Kuwait, with an increasingly significant prevalence 
over the years and mean onset of the disease appearing at 
a younger age  [2] . This is apparent in a systematic review 
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 Abstract 
 Objective: This study examined statin adherence amongst 
Kuwaiti hypercholesterolemic patients in order to identify 
factors associated with poor adherence and to determine 
whether or not an association exists between statin adher-
ence and the risk profile of coronary heart disease (CHD). 
 Subjects and Methods: Two hundred hypercholesterolemic 
patients (30–69 years of age) were recruited from Kuwaiti 
primary healthcare clinics and interviewed about demo-
graphic characteristics, pre-existing self-reported medical 
conditions and prescribed medications. The Morisky Medi-
cation Adherence Scale was used to assess statin adherence 
(a self-reported, medication-adherence questionnaire divid-
ed into 3 levels, with a score of 8 denoting high adherence, 
6 to <8 denoting medium adherence and <6 denoting low 
adherence). Data regarding anthropometric, psychological 
and serum risk factors were collected using 2 additional 
questionnaires, laboratory tests and bioelectrical imped-
ance scales. Binary logistic regression was used to determine 
predictors of adherence and general linear modelling was 
used to test relationships between continuous outcomes 
and statin adherence.  Results: Of the 200 participants, 117 
(58.5%) reported low adherence, 83 (41.5%) reported medi-
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by Elshourbagy et al.  [3] , who reported heart disease as 
being most common among people aged  ≥ 65 years and 
also an increase in the number of sudden deaths from 
heart disease among younger individuals (15–34 years).
 Hypercholesterolemia is associated with an increased 
risk of CHD  [4] . Practices for efficacious prevention of 
CHD include lifestyle changes and life-long statin thera-
py; however, poor adherence limits the benefits of these 
drugs  [4] . Adherence is a key factor associated with the 
efficacy of all pharmacological therapies, including statins 
 [5].  Liberopoulos et al.  [6] identified high rates of discon-
tinuation of statin therapy as a major health issue associ-
ated with unfavourable cardiovascular outcome; they re-
ported that as many as 60% of their patients stopped tak-
ing statins during the first 6 months following the 
initiation of the treatment.
 Common determinants of poor statin adherence in-
clude a lack of education, poor trust of the physician, un-
desired side effects and inadequate provider-patient com-
munication  [7] . Accordingly, a randomized controlled 
trial by Yilmaz et al.  [8] indicated that being well-in-
formed about statins increased the likelihood of continu-
ity of statin therapy at 15 months post-prescription by 
approximately 2-fold. This finding indicated that provid-
ing patients with comprehensive knowledge about statins 
seemed not only to improve adherence but also to in-
crease the likelihood of reaching targets  [8] .
 Although statin prescription for hypercholesterolemia 
is common in the Gulf region  [9] , there is no published 
account of statin adherence and its potential determi-
nants specific to these populations. This study aimed to 
assess the prevalence of statin adherence, the factors as-
sociated with adherence and the risk profile trends of 
CHD associated with low adherence in patients pre-
scribed statins in Kuwait.
 Subjects and Methods 
 Participants and Recruitment 
 Twelve polyclinic/general practice clinics across 4 of the 6 gov-
ernorates in Kuwait (i.e. Al Asimah, Al-Farwaniya, Hawalli and 
Mubarak Al-Kabir) were visited for this study. Consecutive pa-
tients (any health condition) attending these clinics from October 
2011 to October 2012 were approached until a sufficient number 
of patients per clinic was assessed. The sample size was determined 
using the modified version of the approach advocated by Green 
 [10] , which is as follows: n > 50 + 8k,  where ‘k’ is the number of 
parameters included in the model (i.e. adherence, age, gender and 
governorate). There are 16 parameters associated with the main 
effects, yielding a proposed sample size of n = 50 + 8 × 16 = 178. 
Consequently, a sample size of n = 200 was used. Participants were 
informed of the purpose of the study, the benefits of the research 
and any risks associated with participation, and were then asked to 
provide both verbal and written consent. Ethical approval was ob-
tained from the Griffith University Human Research Ethics Com-
mittee and the Medical Research Ethics Committee in the Kuwait 
Institute of Medical Specialisation within the Ministry of Health in 
Kuwait.
 A brief, face-to-face screening was conducted (by M.F.) to se-
lect subjects suitable for the study, based on the following inclusion 
criteria: Kuwaitis of both genders, aged 30–69 years, living in both 
urban and rural governorates, having hyperlipidemia (classified as 
total serum cholesterol levels of >7.8 mmol/l)  [13] but free of diag-
nosed CHD and on prescribed statins for at least 6 months prior 
to the first interview (the initiation of statin therapy for patients 
involved in the study ranged between 6 and 24 months prior to 
study participation). Accordingly, 200 patients were chosen. Data 
on demographic characteristics, pre-existing self-reported medical 
conditions (e.g. hypercholesterolemia, hypertension and diabetes) 
and prescribed medications were also collected from the partici-
pants. Patients’ medical records were reviewed to confirm the self-
reports. The data collected by these 2 methods were then combined 
for analysis.
 Data Assessment 
 Three questionnaires were used to collect the relevant data. The 
first was on sociodemographic and clinical factors including age, 
gender, work status, governorate, smoking status, current or past 
use of all medications, duration and type of statin intake and pre-
vious diabetic/hypertensive conditions. The second consisted of 
the Depression, Anxiety and Stress Scale (DASS)  [14] , used (by 
M.F.) to assess affective disorder status. Interpretation of the DASS 
was based primarily on the use of cut-off scores provided by Lovi-
bond and Lovibond  [15] : severity ratings were classified as normal 
(D 0–9, A 0–7, S 0–14), mild (D 10–13, A 8–9, S 15–18), moderate 
(D 14–20, A 10–14, S 19–25), severe (D 21–27, A 15–19, S 26–33) 
and extremely severe (D 28+, A 20+, S 34+) on the basis of com-
bined collective scores in every subscale category  [15] . The third 
was the 8-item self-report Morisky Medication Adherence Scale 
(MMAS)  [16] , used to measure adherence levels to statin therapy, 
i.e. atorvastatin (Lipitor), simvastatin (Zocor) or rosuvastatin 
(Crestor). The MMAS score was divided into 3 levels of adherence: 
8 = high, 6 to <8 = medium and <6 = low  [16] . Permission to use 
the MMAS was granted by David E. Morisky himself, hence, a 
waiver of licensure fee was also received (permission submitted).
 An anthropometric assessment was also conducted. Initially, 
height and weight were measured using a Seca 217 stadiometer 
(Hamburg, Germany)  [17] , and the Omron body fat analyser, 
Model HBF-500 (Omron Medizintechnik, Mannheim, Germany) 
 [18] , respectively. Bioelectrical impedance assessment was then 
carried out, by which the participant’s height, gender and age were 
entered into the Omron body fat analyser, Model HBF-500. This 
device uses 8 electrodes in a tetrapolar arrangement that requires 
the subject to stand on metal footpads in bare feet and grasp a pair 
of electrodes fixed on a handle with arms extended in front of the 
chest  [18] . They are instructed to hold the analyser according to 
the manufacturer’s directions (arms extended from body and per-
pendicular to the floor, thumbs on top). The estimate of body fat 
percentage and skeletal muscle mass were recorded, along with the 
computed BMI value. Subjects were categorised according to the 
following: underweight = BMI <20.0, healthy = BMI 20.0–24.9, 
overweight = BMI 25.0–29.9 and obese = BMI >30.0.
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 In addition, a risk profile for each patient was constructed from 
serum risk factor measurements in medical records collected as 
part of usual care. These included a complete lipid profile and 
blood chemistry, i.e. levels of glucose, serum cholesterol, triglycer-
ides, high-density lipoprotein (HDL), low-density, lipoprotein 
(LDL) and very-low-density lipoprotein (VLDL) cholesterol in the 
blood. Factors that increased the risk of developing CHD  [19–21] 
were based on  ≥ 1 of the following criteria: blood glucose  ≥ 6.1 
mmol/l, hypertriglyceridemia  ≥ 1.69 mmol/l, HDL cholesterol 
<1.04 mmol/l in men and <1.29 mmol/l in women, and LDL cho-
lesterol  ≥ 3.4 mmol/l.
 Statistical Analysis 
 All analyses were performed using STATA (Statistics and Data 
v11.0, Stata Corp., College Station, Tex., USA)  [22] Descriptive 
analysis using cross-tabulations (contingency tables) were initial-
ly carried out to establish an interdependent relationship between 
various research variables, such as statin adherence and age, gen-
der, area of residence and work status. Binary logistic regression 
was then used to determine predictors of the dichotomous vari-
able, statin adherence (low/medium). Associations between risk 
factors and the outcomes were gauged using odds ratios (ORs). 
Independent Student’s t tests and general linear modelling were 
used to test relationships between continuous outcomes (e.g. 
blood chemistry) and statin adherence (categorical variables). 
Model building was performed using a modified version of the 
Purposeful Selection of Covariates (PSC) approach outlined by 
Hosmer et al.  [23] . The PSC was modified to consider a study ef-
fect where gauging the significance of a particular risk factor was 
the primary outcome (i.e. statin adherence) with identifying other 
risk factors as secondary outcomes (i.e. blood chemistry). Statin 
adherence was therefore forced into each step of this 3-step mod-
el, regardless of its statistical significance, to ensure that the re-
search hypothesis was being addressed. However, when statin ad-
herence was measured as an outcome, the exact model-building 
protocol advocated by Hosmer et al.  [23]  was employed, since 
there was no single-study effect and the modelling process became 
more exploratory (determination of risk factors associated with 
adherence).
 Results 
 The distribution of subjects based on socio-demo-
graphic characteristics is shown in  table 1 . According to 
the Yes/No answers provided by the participants regard-
ing smoking, 177 of the 200 participants (88.5%) reported 





30 – 50 years 56 (28)
51 – 60 years 75 (37.5)










Low (<6) 117 (58.5)
Medium (6 to <8) 83 (41.5)
High (8) 0 (0)
 Table 2.  Gender-specific subject distribution of anthropometric 
variables
Male 63 (31.5)













Mean sex distribution ± SD, %
Males 32.4 ± 5.03
Females 46.1 ± 6.03
Male 63 (31.5)






Extremely obese 2 (3.2)
Female 137 (68.5)






Extremely obese 16 (11.7)
Mean sex distribution ± SD, %
Males 31.1 ± 4.49 
Females 32.4 ± 6.34
Values express n (%), unless otherwise indicated. Percentage 
body fat was measured using an Omron body fat analyser.
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being non-smokers, 23 (11.5%) reported smoking tobac-
co and only 1 was female.
 A high prevalence of obesity was identified in our sub-
jects, indicated by body fat percentage, in 49 (77.8%) 
males and 117 (85.4%) females, and BMI measurement, 
in 35 (55.6%) males and 86 (62.8%) females ( table  2 ). 
Gender-specific subject distributions for anthropometric 
and clinical measures are presented in  tables 2 ,  3 . 
 Depression, anxiety and stress cut-off points were a 
cumulative score of 21–27 points on the DASS 4-point 
Likert scale for depression, 15–19 for anxiety and 34+ for 
stress  [15] . Of the 200 participants, 1 (2%), 21 (10.5%) and 
6 (3%) exceeded the cut-off points for depression, anxiety 
and stress, respectively.
 Of the 200 participants, 87 (43.5%) reported having 
diabetes, 84 (42%) reported being hypertensive, 73 
(36.5%) reported being free of both diabetes and hyper-
tension and 44 (22%) reported having both.
 Of the 200 participants, 117 (58.5%) reported low ad-
herence, 83 (41.5%) reported medium adherence and 
none reported high adherence ( table  1 ). Twenty-seven 
male (42.9%) and 56 female (40.9%) subjects had a high-
er statin adherence. However, based on the two-way con-
tingency analysis, the difference was not statistically sig-
nificant.
 Preliminary bivariate analysis revealed 4 statistically 
significant predictors of statin adherence: age, diabetes, 
hypertension and the duration of statin intake. However, 
after adjusting for the confounders, gender, smoking and 
diabetes, in the final multivariable model, both age and 
diabetes remained associated with statin adherence level. 
The odds of medium adherence were 1.05 times [95% 
confidence interval (CI) 1.01–1.09] higher than that of 
low adherence for every extra year of age (p < 0.01;  ta-
ble 4 ). Participants without diabetes had 0.42 times (95% 
CI 0.23–0.75) the odds of medium adherence (lower odds 
of medium adherence), relative to those with diabetes
(p < 0.01;  table 4 ).
 Low statin adherence was associated with higher plas-
ma cholesterol at p < 0.001 and p < 0.01, for males and 
females, respectively, and higher LDL cholesterol levels at 
p < 0.01 for both males and females ( table 5 ).
 Discussion 
 In this study on patients with hypercholesterolemia, 
statin adherence was generally poor. Based on the MMAS, 
not one of the 200 subjects was classified as highly adher-
ent to statin therapy, and more than half were classified 
 Table 4.  ORs of associations between adherence to statin medica-





 95% CI for
difference*
lo wer upper
Age 1.05** 1.05** 1.01 1.09





Smoker 0.91 0.69 0.23 2.07








χ2LR (d.f. = 4) 17.97
p value (χ2LR) 0.0013
Al-Asimah and treatment with atorvastatin are not shown in 
the table as they are the referents (the group against which the
others are compared) for the remaining governorates (Hawalli, Al-
Farwaniya, Mubarak Al-Kabir) and statins (Zocor, Crestor). * p < 0.05, ** p < 0.01.









lo w normal high
Cholesterol 4.9 ± 1.2 2.5 – 8.9 200 1.5 66.5 32
Males 5.1 ± 1.4 2.5 – 8.9 63 3.2 54 42.9
Females 4.8 ± 1 2.6 – 7.7 137 0.7 72.3 27
Triglycerides 1.8 ± 2.5 0.34 – 35.1 197 0.5 80.2 19.3
Males 2.4 ± 4.3 0.50 – 35.1 62 0 69.4 30.6
Females 1.5 ± 0.8 0.34 – 6.4 135 0.7 85.2 14.1
HDL 1.3 ± 0.3 0.57 – 2.6 180 20 77.2 2.8
Males 1 ± 0.2 0.68 – 1.7 55 40 60 0
Females 1.3 ± 0.3 0.57 – 2.6 125 11.2 84.8 4
LDL 2.9 ± 1 0.7 – 6 178 43.2 32.4 24.4
Males 3 ± 1.2 0.7 – 5.8 53 34.6 30.8 34.6
Females 2.8 ± 0.96 1.3 – 6 125 46.8 33.1 20.2
VLDL 0.8 ± 1.4 0.14 – 14.1 101 39.6 58.4 2
Males 1.3 ± 2.6 0.26 – 14.1 27 25.9 70.4 3.7
Females 0.7 ± 0.4 0.14 – 2.9 74 44.6 54.1 1.4
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as having low adherence. These levels were much lower 
than those reported by Natarajan et al.  [24] (63% high 
adherence in Canada) and Cutler et al.  [25] (36.5% high 
statin adherence levels in New Jersey). This contrast in 
statin adherence between previous studies and our find-
ings is of significant concern; low adherence limits the 
effectiveness of statins, thus compromising primary pre-
vention of myocardial infarction  [4] .
 The findings that adherence to statins was higher in 
older than younger patients and those with a prior his-
tory of diabetes confirmed those of Latry et al.  [26] who 
reported higher adherence in those patients with an in-
creased number of associated cardiovascular risk factors 
including older age, diabetes and other cardiovascular 
disease comorbidities. They suggested that older patients 
with several risk factors were probably more aware of 
their own mortality and thus more attentive to their treat-
ment than younger patients. It is also plausible that pa-
tients with diabetes had experienced the consequence of 
non-adherence to a specific medication, and hence be 
more aware and attuned to these health consequences.
 Higher adherence to statin therapy was inversely as-
sociated with plasma cholesterol and LDL levels, with 
overall effect size values of –12.7 and –19.2%, respective-
ly, suggesting that these differences may also be of clinical 
importance.
 Furthermore, subjects who had been on statin medica-
tion longer had lower plasma cholesterol, glucose and 
LDL levels. Hence, statin prescription was effective in low-
ering CHD risk. Psychosocial factors were not associated 
with statin adherence in our study, thus contradicting 
findings from previous studies that recognised depression 
as one of the most important factors affecting adherence 
to medical treatment  [27–30] . Our results revealed no sig-
nificant difference in adherence between depressed and 
non-depressed patients; a study by Weilburg et al.  [28] 
indicated that depressed hyperlipidemic diabetic patients 
refilled their statin prescriptions less often than those 
without depression; this suggests lower adherence  [28] . 
Their study also revealed that patients receiving adequate 
anti-depressants were twice as likely to adhere to chronic-
disease medications (including statins) than patients re-
ceiving inadequate anti-depressant treatment  [28] . In ad-
dition, a study by Sulaiman et al.  [29]  revealed that de-
pressed Arab patients in the United Arab Emirates were 
less likely to adhere to prescribed healthcare regimens.
 Conclusion 
 In this study, there was an inverse relationship be-
tween high adherence to statin therapy and plasma levels 
of cholesterol and LDL, suggesting that statin prescrip-
tion is effective in improving CHD risk profile. Subjects 
with concomitant diabetes were more responsive to statin 
therapy, while younger patients with fewer concurrent 
diseases showed lower treatment adherence. Future re-
search is required to establish the reasons for the differ-
ences in adherence between various Kuwaiti subject 
groups and to determine how to enhance overall statin 
adherence in the early stages of prescription.
 







Cholesterol low 5.53 1.0 (0.33 to 1.66)***
medium 4.53
TG low 1.78 –1.43 (–3.64 to 0.77)
medium 3.21
HDL low 1.14 0.21 (0.09 to 0.33)**
medium 0.93
LDL low 3.44 0.84 (0.26 to 1.42)**
medium 2.60
VLDL low 0.77 –0.93 (–2.98 to 1.11)
medium 1.71
Females
Cholesterol low 5.02 0.60 (0.25 to 0.95)**
medium 4.42
TG low 1.43 –0.09 (–0.37 to 0.19)
medium 1.52
HDL low 1.35 0.01 (–0.11 to 0.13)
medium 1.34
LDL low 3.01 0.61 (0.28 to 0.94)**
medium 2.40
VLDL low 0.69 –0.01 (–0.21 to 0.20)
medium 0.70
 TG = Triglycerides. * p < 0.05, ** p < 0.01, *** p < 0.001.
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